Editor's note

This article was originally published on 12 December 2014 as part of the VacZine Analytics ExpertREACT series. It is reproduced here for archival purposes. Market conditions, pipeline statuses and regulatory positions described reflect the state of knowledge at that date.

VacZine Analytics presents its annual review of the most significant vaccine industry events of 2014. The year was marked by historic M&A, pivotal Phase III data and an unprecedented public health emergency that accelerated vaccine development like nothing in recent memory.

The top ten events of 2014

  1. TRUMENBA (Pfizer) approved in the US (10-25 years) - The second meningococcal serogroup B vaccine to reach the US market, marking a new era in MenB prevention for adolescents.
  2. First Phase III efficacy data from Sanofi's dengue vaccine - CYD-TDV (Dengvaxia®) demonstrated approximately 60.8% overall efficacy in both Asian and Latin American Phase III studies, a historic first for dengue.
  3. Acquisition of Novartis Vaccines business (excluding influenza) by GSK - The $5.25 billion deal transformed the meningococcal and travel vaccine landscape, bringing Bexsero®, Menveo® and the travel portfolio under GSK.
  4. Acquisition of Novartis Vaccines influenza business by BioCSL - The Australian company took on the Novartis influenza franchise including Fluvirin, reshaping the global influenza supply landscape.
  5. Largest Ebola virus epidemic in history and subsequent Phase I data of fast-tracked candidates - The West African outbreak exceeded all prior records and triggered unprecedented emergency clinical development of ChAd3 (NIH/GSK) and VSV-ZEBOV (NewLink/PHAC) candidates.
  6. CAPiTA trial results: PCV-13 (Pfizer) prevents community-acquired pneumonia in adults >65 years - The landmark randomised controlled trial demonstrated vaccine-type pneumococcal pneumonia prevention in older adults, strengthening the case for adult PCV use.
  7. Pfizer acquires Baxter's portfolio of vaccines - A $635 million acquisition adding NeisVac-C (MenC) and FSME-Immun (tick-borne encephalitis) to Pfizer's portfolio.
  8. Publication of FIM12 study: Fluzone HD provides additional protection in adults >65 years - The 15,892-person trial showed a 24.2% relative efficacy advantage of high-dose over standard Fluzone.
  9. US FDA Fast Track designation of Pfizer's Clostridium difficile vaccine (Phase II) - Recognition of the significant unmet need in nosocomial infection prevention.
  10. India's provision of the pentavalent paediatric combination vaccine for all infants - A landmark expansion of childhood immunisation coverage in the world's second most populous country.

"The most surprising event of 2014 must be that the industry found itself racing to develop an Ebola vaccine - a scenario few had planned for."